home / stock / allr / allr news

ALLR News and Press, Allarity Therapeutics Inc. From 07/05/23

Stock Information
Company Name: Allarity Therapeutics Inc.
Stock Symbol: ALLR
Market: NASDAQ
Website: allarity.com
Menu
ALLR ALLR Quote ALLR Short ALLR News ALLR Articles ALLR Message Board
Get ALLR Alerts

News, Short Squeeze, Breakout and More Instantly...
ALLR - Initial Data from Allarity's Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients

Boston , MA (July 5, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP ® companion diagnostics for p...
ALLR - Allarity Therapeutics clarifies on effective reverse stock split date

2023-06-28 01:55:32 ET Clinical-stage pharmaceutical company, Allarity Therapeutics ( NASDAQ: ALLR ) clarifies the effective date of its contemplated reverse stock split. The company is clarifying that the reverse stock split will not be effected on June 27, 2023,...

ALLR - Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split

Press Release BOSTON, MA (June 27, 2023) – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP ® companion diagnos...

ALLR - Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders

Meeting adjourned to Friday, June 23 , 2023 at 1 :00 p .m. Eastern Time Press release BOSTON, MA (June 20, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage ...
ALLR - First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting

Phase 2 study e valuating the u tility of a DRP ® c ompanion d iagnostic for cisplatin support s its ability to predict drug response in certain breast cancer patients Boston , M A (May 30, 2023) — A...

ALLR - Allarity Therapeutics Accelerates Trial Enrollment To Bring FDA-Approved Breast Cancer Treatment To European Market - Interim Results Could Be Released In Second Half Of 2023

CAMBRIDGE, MA / ACCESSWIRE / April 27, 2023 / Recently, Allarity Therapeutics, Inc. (NASDAQ:ALLR) announced plans to speed up its Phase 2 clinical trial for IXEMPRA®, the clinical-stage pharma company's metastatic breast cancer treatment. Already approved by the Food and Drug Administ...

ALLR - BBBY, CTXR and HTGM among mid-day movers

2023-04-19 12:49:23 ET Gainers: SAI.TECH Global Corporation ( SAI ) +48% . Bed Bath & Beyond ( BBBY ) +40% . VYNE Therapeutics ( VYNE ) +34% . Boqii Holding Limited ( BQ ) +30% . CXApp ( CXAI ) +19% . Western Alliance Ban...
ALLR - Vyne, Ensysce top healthcare gainers; Allarity, Femasys lead losers' pack

2023-04-19 10:05:08 ET Gainers: Vyne Therapeutics ( VYNE ) +32% . Ensysce Biosciences ( ENSC ) +23% . Legend Biotech ( LEGN ) +20% . Tempest Therapeutics ( TPST ) +16% . Evoke Pharma ( EVOK ) +14% . Losers: Allarity T...

ALLR - Allarity Therapeutics stock slides after pricing $7.5M securities offering

2023-04-19 09:48:03 ET Allarity Therapeutics ( NASDAQ: ALLR ) shares plunged 40% on Wednesday after the pharmaceutical company priced its securities offering to raise around $7.5M in gross proceeds. The offering consists of 2,869,330 shares of common stock, 7,130,670 p...

ALLR - Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering

Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering BOSTON, MA (April 19, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeu...
Previous 10 Next 10